AU2013201780B2 - Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof - Google Patents

Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Download PDF

Info

Publication number
AU2013201780B2
AU2013201780B2 AU2013201780A AU2013201780A AU2013201780B2 AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2 AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
mmol
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013201780A
Other languages
English (en)
Other versions
AU2013201780A1 (en
Inventor
Christopher John Burns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YM Biosciences Australia Pty Ltd
Original Assignee
YM Biosciences Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YM Biosciences Australia Pty Ltd filed Critical YM Biosciences Australia Pty Ltd
Priority to EP13809739.9A priority Critical patent/EP2867238B1/en
Priority to CN201380041191.XA priority patent/CN104583216A/zh
Priority to NZ703343A priority patent/NZ703343A/en
Priority to ES13809739.9T priority patent/ES2644606T3/es
Priority to PCT/AU2013/000687 priority patent/WO2014000032A1/en
Priority to CA2877923A priority patent/CA2877923C/en
Priority to PT138097399T priority patent/PT2867238T/pt
Priority to HK15109468.7A priority patent/HK1208861A1/xx
Priority to HK15109881.6A priority patent/HK1209120B/en
Priority to JP2015518724A priority patent/JP5931288B2/ja
Publication of AU2013201780A1 publication Critical patent/AU2013201780A1/en
Application granted granted Critical
Publication of AU2013201780B2 publication Critical patent/AU2013201780B2/en
Priority to JP2015178970A priority patent/JP6153980B2/ja
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013201780A 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Ceased AU2013201780B2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PT138097399T PT2867238T (pt) 2012-06-29 2013-06-26 Compostos bicíclicos de fenil amino pirimidina e utilizações dos mesmos
NZ703343A NZ703343A (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
ES13809739.9T ES2644606T3 (es) 2012-06-29 2013-06-26 Compuestos bicíclicos de fenil amino pirimidina y usos de los mismos
PCT/AU2013/000687 WO2014000032A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
CA2877923A CA2877923C (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
HK15109468.7A HK1208861A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
EP13809739.9A EP2867238B1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
HK15109881.6A HK1209120B (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN201380041191.XA CN104583216A (zh) 2012-06-29 2013-06-26 苯基氨基嘧啶双环化合物及其用途
JP2015518724A JP5931288B2 (ja) 2012-06-29 2013-06-26 フェニルアミノピリミジン二環式化合物およびその使用
JP2015178970A JP6153980B2 (ja) 2012-06-29 2015-09-10 フェニルアミノピリミジン二環式化合物およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666725P 2012-06-29 2012-06-29
US61/666,725 2012-06-29

Publications (2)

Publication Number Publication Date
AU2013201780A1 AU2013201780A1 (en) 2014-01-16
AU2013201780B2 true AU2013201780B2 (en) 2015-04-02

Family

ID=49778746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013201780A Ceased AU2013201780B2 (en) 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof

Country Status (11)

Country Link
US (1) US8809359B2 (enExample)
EP (1) EP2867238B1 (enExample)
JP (2) JP5931288B2 (enExample)
CN (1) CN104583216A (enExample)
AU (1) AU2013201780B2 (enExample)
CA (1) CA2877923C (enExample)
ES (1) ES2644606T3 (enExample)
HK (1) HK1208861A1 (enExample)
NZ (1) NZ703343A (enExample)
PT (1) PT2867238T (enExample)
WO (1) WO2014000032A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
EP3255129B1 (en) * 2016-06-06 2024-01-24 The Lubrizol Corporation Thiol-carboxylic adducts as lubricating additives
CN108707119A (zh) * 2018-06-25 2018-10-26 抚顺大恒化工有限公司 一种Momelotinib的制备方法
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法
IL297437A (en) 2020-05-13 2022-12-01 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN117624189B (zh) * 2023-11-24 2025-11-11 上海馨远医药科技有限公司 一种6-氧杂-3-氮杂双环[3.1.1]庚烷盐酸盐的制备方法
CN117986179A (zh) * 2024-01-16 2024-05-07 深圳市茵诺圣生物科技有限公司 一种顺式-4-羟基-l-脯氨酸的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
CA2441733A1 (en) 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
CN100366289C (zh) 2001-09-12 2008-02-06 维日克斯医药公司 具有固定的血小板结合剂的血管闭塞固相试剂
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
CA2506772A1 (en) 2002-11-01 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
ATE371656T1 (de) 2002-11-04 2007-09-15 Vertex Pharma Heteroaryl-pyrimidinderivate als jak-inhibitoren
AU2003286895A1 (en) 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
JP2007500179A (ja) 2003-07-30 2007-01-11 サイクラセル・リミテッド キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
WO2006044457A1 (en) 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
WO2007101232A2 (en) 2006-02-28 2007-09-07 Cytopia Research Pty, Ltd. Inhibition of jak2 as a treatment of pulmonary arterial hypertension
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0820544A2 (pt) * 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
LT2265607T (lt) * 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
CN102112131A (zh) 2008-08-05 2011-06-29 塔格根公司 治疗地中海贫血的方法
WO2011113802A2 (en) * 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
SG10201509919UA (en) 2010-12-03 2016-01-28 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
MD20130089A2 (ro) 2011-05-02 2014-05-31 Ym Biosciences Australia Pty Ltd Metodă de tratament al mielomului multiplu
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Also Published As

Publication number Publication date
CA2877923A1 (en) 2014-01-03
WO2014000032A1 (en) 2014-01-03
JP2016028076A (ja) 2016-02-25
JP6153980B2 (ja) 2017-06-28
NZ703343A (en) 2015-12-24
AU2013201780A1 (en) 2014-01-16
ES2644606T3 (es) 2017-11-29
PT2867238T (pt) 2017-10-30
HK1209120A1 (en) 2016-03-24
JP2015525738A (ja) 2015-09-07
EP2867238B1 (en) 2017-08-09
CA2877923C (en) 2017-07-25
EP2867238A4 (en) 2015-05-06
US20140005161A1 (en) 2014-01-02
EP2867238A1 (en) 2015-05-06
US8809359B2 (en) 2014-08-19
CN104583216A (zh) 2015-04-29
JP5931288B2 (ja) 2016-06-08
HK1208861A1 (en) 2016-03-18

Similar Documents

Publication Publication Date Title
AU2013201780B2 (en) Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof
AU2008210266B2 (en) Thiopyrimidine-based compounds and uses thereof
AU2008226327B2 (en) Phenyl amino pyrimidine compounds and uses thereof
TWI851563B (zh) 作為免疫調節劑之雜環化合物
EP2215094B1 (en) N-containing heterocyclic compounds
AU2016200866B2 (en) Phenyl amino pyrimidine compounds and uses thereof
HK1209120B (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
AU2013201306B2 (en) Phenyl Amino Pyrimidine Compounds and Uses Thereof
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
TW202313014A (zh) 作為ｐｄ－ｌ１相互作用的免疫調節劑的雜環化合物
AU2013248233A1 (en) N-containing heterocyclic compounds
HK1147252B (en) N-containing heterocyclic compounds
HK1223619A1 (en) Phenylaminopyrimidine compound and use thereof
AU2013263739A1 (en) Thiopyrimidine-based Compounds And Uses Thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired